白云山和黄品牌怎么样 申请店铺

我要投票 白云山和黄在医疗器械行业中的票数:165 更新时间:2025-04-01
白云山和黄是哪个国家的品牌?「白云山和黄」是 广州白云山医药集团股份有限公司 旗下著名品牌。该品牌发源于广东省广州市,由创始人李楚源在1997-09-01期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力白云山和黄品牌出海!通过在本页面挂载白云山和黄品牌的产品链接和联系邮箱,可以提高白云山和黄产品曝光!跨境电商爆单神器,目前只要100元/年哦~

白云山和黄怎么样

始建于1988年,广州白云山医药集团旗下,其板蓝根产品享誉业界,华南地区较大的单体中药生产企业


广州白云山和记黄埔中药有限公司(以下简称“白云山和黄”),由广药集团白云山制药股份有限公司与爱国商人李嘉诚先生旗下和记黄埔(中国)公司于2005年5月合资成立。合资公司前身为广州白云山中药厂,成立于1988年5月,是由1956年组建的农场作业区脱胎而来,并过渡到农工并举的滋补品厂,进而转为经营医药健康事业的广州白云山中药厂。

公司站在时代的前沿和行业的高度,以“教育、爱心、科技、创新、责任”十字方针为指南,以“中药现代化、中药国际化、中药大众化、中药科普化”为使命,以经济效益为中心,内抓管理,外拓市场,实施“人才、品牌、科技”三大战略,形成了科技创新、责任营销、文化传承、人才工程、党建先进五大核心竞争优势。尤其是1999年以来,公司步入高速成长期,实现了跨越式发展。1999年—2013年,企业规模扩大30倍,销售、回款、产值、利润四项指标保持30%以上增长。公司积极打造现代中药先锋企业,向大健康产业优势企业进军。

公司重金打造“神农草堂”中医药博物馆及以神农精神为核心的企业文化,做强文化健康,让更多的人认识、了解和接受中医药。“神农草堂”融知识性、趣味性,集中医药历史、文化及中草药种植于一体,现已接待海内外游客超80万人次,成为雅俗共赏的中医药文化传播典范之作。


Founded in 1988, Guangzhou Baiyunshan Pharmaceutical Group, whose Banlangen products are well-known in the industry, Guangzhou Baiyunshan Hutchison Huangpu traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison"), a large single traditional Chinese medicine manufacturer in South China, was founded in May 2005 by Baiyunshan Pharmaceutical Co., Ltd. of Guangzhou Pharmaceutical group and Hutchison Huangpu (China) Co., Ltd. of patriotic businessman Li Jiacheng Joint venture. The joint venture company, formerly known as Guangzhou Baiyunshan traditional Chinese medicine factory, was founded in May 1988. It was born out of the farm operation area established in 1956, and then transferred to a nourishing factory with both agriculture and industry, and then to Guangzhou Baiyunshan traditional Chinese medicine factory which is engaged in medical and health undertakings. Standing at the forefront of the times and at the height of the industry, guided by the cross policy of "education, love, science and technology, innovation and responsibility", with the mission of "modernization, internationalization, popularization and popularization of traditional Chinese medicine", centering on economic benefits, focusing on internal management, expanding the market and implementing the three strategies of "talent, brand and technology", the company has formed scientific and technological innovation and responsibility Serve as the five core competitive advantages of marketing, cultural heritage, talent engineering and advanced Party construction. Especially since 1999, the company has stepped into a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, payment collection, output value and profit kept growing by more than 30%. The company actively builds a modern Chinese medicine pioneer enterprise, and advances to a large health industry advantage enterprise. The company has invested heavily in building "shennongcaotang" TCM Museum and corporate culture with Shennong spirit as the core to strengthen cultural health and let more people know, understand and accept TCM. "Shennong Caotang" integrates knowledge and interest, focusing on the medical history, culture and planting of Chinese herbal medicine. It has now received more than 800000 tourists at home and abroad, and has become a model of cultural communication of traditional Chinese medicine for both refined and popular tastes.

本文链接: https://brand.waitui.com/1a1b8b398.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

转转集团成立AI事业部,预计3年投入20亿

36氪获悉,4月1日,转转集团宣布成立转转AI事业部(ZAI)。转转集团CEO黄炜在公开平台发布信息表示,计划结合二手领域的信任痛点和C2B2C模式下的闭环数据,打造多款二手领域的行业AI智能工具,包括转转买家智能体ZAIBA、转转官方验智能体ZAIYA以及转转混合智能体ZAIMA,并决定三年内投入“保守估计20亿”。旨在利用AI解决二手交易中的非标问题,打造二手交易新体验。同时,黄炜表示,转转已启动全球AI人才招募计划,重点引进AI相关产品和研发人才。

2小时前

中国3月财新制造业PMI 51.2,前值50.8

2025年3月,随着春节后企业经营活动逐渐恢复,中国制造业景气扩张步伐继续加快。4月1日公布的3月财新中国制造业采购经理人指数(PMI)录得51.2,高于上月0.4个百分点,为四个月来新高。国家统计局此前一天公布的3月制造业PMI录得50.5,较上月上升0.3个百分点,连续两月处于扩张区间,并录得2024年4月以来最高。(财新)

2小时前

新型城镇化概念盘初活跃,建艺集团涨停

36氪获悉,截至发稿,新型城镇化概念盘初活跃,建艺集团涨停,山水比德涨超10%,地铁设计、新城市、霍普股份、筑博设计等涨幅居前。

2小时前

脑机接口概念快速拉升,创新医疗直线涨停

36氪获悉,截至发稿,脑机接口概念快速拉升,创新医疗直线涨停,爱朋医疗涨超10%,三博脑科、诚益通、塞力医疗、国际医学等跟涨。

2小时前

中信建投:券商2024业绩显著修复,看好一季度盈利弹性继续释放

36氪获悉,中信建投表示,2024年券商业绩显著修复,核心驱动来自政策利好、自营收益正增及2023年低基数效应。2025年,市场交投持续回暖下,股基交易额、融资余额及权益基金发行有望继续提升,继续提振券商财富管理收入,叠加去年一季度自营投资低基数的影响,行业盈利弹性或会继续释放。当前券商板块兼具估值安全边际与政策催化预期,建议持续关注。

2小时前

本页详细列出关于尼德克NIDEK的品牌信息,含品牌所属公司介绍,尼德克NIDEK所处行业的品牌地位及优势。
咨询